REG-Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
Key Highlights
- ➤PREDICT-1 registrational dry-eye trial topline readout remains on track around year-end
- ➤Oculis will present Licaminlimab at Eyecelerator @ AAO 2026 on October 8
- ➤Oculis will sponsor AAO 2026 Neuro-Ophthalmology Subspecialty Day on October 9
- ➤Privosegtor is being evaluated in three registrational trials under the PIONEER program
Expert Statements
Riad Sherif, M.D., Chief Executive Officer of Oculis
“AAO provides a valuable opportunity to engage with the broader ophthalmology and neuro-ophthalmology communities and discuss how innovation can address persistent unmet needs in both fields. The upcoming topline results from PREDICT-1 have the potential to further advance our aim of bringing precision medicine to TNFR1-mediated dry eye disease, while the continued progress of Privosegtor reflects our commitment to transforming outcomes for patients facing neuro-ophthalmic diseases. Together, these programs illustrate Oculis’ strategy of pursuing highly differentiated therapies with the potential to redefine standards of care.”
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end
ZUG, Switzerland, October 7, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculis, will present at Eyecelerator @ AAO 2026 on October 8, 2026, and that the Company will sponsor the Neuro-Ophthalmology Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting on October 9, 2026, in New Orleans, Louisiana.
Get started
Create a free account to read the full story.